Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Cachexia
Interventions: GSK2881078, Placebo, Itraconazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: ASC42, Placebo; Drug
Lead sponsor: Gannex Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 2 Diabetes Mellitus
Interventions: BMF-219, Placebo; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 443 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 36
States / cities: Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more

Conditions: Obesity
Interventions: NO-13065, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Factory, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Circadian Rhythm Sleep Disorders
Interventions: VEC-162; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Healthy
Interventions: STSA-1002 injection, Placebo; Drug
Lead sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: Placebo, Rasigiline, Phenelzine, Ozanimod; Other · Drug
Lead sponsor: Celgene; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy
Interventions: PF-06291874, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions: HT-2157, Placebo; Drug
Lead sponsor: Dart NeuroScience, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Adults, Elderly Subjects
Interventions: TD-0714, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Typhoid
Interventions: Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3), Dose of of 1.7 x 10^10 CFU (Cohort 4), Placebo (Cohorts 1-4 pooled); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: South Miami, Florida • Baltimore, Maryland • Burlington, Vermont

Conditions: Heart Failure, Healthy Volunteer
Interventions: AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more

Conditions: Thrombosis
Interventions: BMS-962212, Aspirin, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 691 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Cypress, California • Glendale, California • Baltimore, Maryland

Conditions: Healthy Participants
Interventions: AZD6234, Placebo, Acetaminophen; Drug · Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Drug Safety, Heart; Disease, Activity
Interventions: CARD-024, Drug Carrier; Drug · Other
Lead sponsor: Cardiavent Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Health Adult Subjects
Interventions: Placebo （Microcrystalline Cellulose）, Dihydroberberine（DHB）; Dietary Supplement
Lead sponsor: Nanjing Nutrabuilding Bio-tech Co., Ltd.; Other
Eligibility: 35 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Healthy
Interventions: AZD9742, Placebo to match AZD9742; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Bipolar Disorder
Interventions: AZD4451, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: TS-134, Placebo; Drug
Lead sponsor: Taisho Pharmaceutical R&D Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Growth Hormone Deficiency
Interventions: ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg, Placebo 0.015 mg/kg, Placebo 0.05mg/kg, Placebo 0.15mg/kg; Drug
Lead sponsor: Aileron Therapeutics, Inc.; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: FTY720; Drug
Lead sponsor: Novartis; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Obesity
Interventions: Peptide YY3-36; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: BLU-782, Placebo, BLU-782 taken with food; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects

Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451

Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers

Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults